Pharmaceuticals

Rise In Cardiovascular Diseases Driving The Growth Of The Market Due To Increasing Prevalence And Demand For Heart-Related Treatments Is Supporting Development Across The Cardiotonic Agents Market

May 18, 2026May 19, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Are The Forecasted Market Size Figures For The Cardiotonic Agents Market In 2026 And 2030?

The market size for cardiotonic agents has seen substantial growth in recent years. It is anticipated to expand from $3.11 billion in 2025 to $3.5 billion in 2026, registering a compound annual growth rate (CAGR) of 12.3%. This historic expansion can be ascribed to several factors, including the rising incidence of heart failure, reliance on inotropic support in critical care, limited alternatives for acute cardiac output improvement, expansion of cardiac surgery procedures, and hospital-centric cardiovascular treatment.

The cardiotonic agents market is projected to experience substantial growth over the next few years, reaching a valuation of $5.56 billion by 2030, at a compound annual growth rate (CAGR) of 12.3%. This expansion during the forecast period can be primarily attributed to factors such as an aging global population, the increasing incidence of advanced heart failure cases, a growing demand for rapid-acting cardiac drugs, the development of critical care infrastructure, and enhanced monitoring capabilities in cardiac intensive care units. Significant trends expected during this period include the continued application of cardiotonic drugs in acute heart failure management, a preference for hospital-based intravenous administration, an ongoing requirement for digitalis glycosides in arrhythmia treatment, the integration of cardiotonic agents within surgical cardiac care, and a gradual transition towards combination cardiovascular therapy.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp

Which Growth Factors Are Strengthening The Cardiotonic Agents Market Landscape?

The increasing occurrence of cardiovascular diseases is anticipated to propel the expansion of the cardiotonic agents market moving ahead. Cardiovascular diseases (CVDs) constitute a range of conditions affecting the heart and blood vessels, including ailments such as coronary artery disease, heart failure, arrhythmias, and stroke. The surge in cardiovascular diseases is primarily due to diets rich in saturated fats, trans fats, salt, and added sugars, which contribute to obesity, elevated blood pressure, and high cholesterol levels. Cardiotonic agents enhance the heart muscle’s efficiency and contractile strength, thereby supporting improved blood circulation and alleviating symptoms in various cardiovascular conditions. For instance, in September 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported 17.9 million deaths from cardiovascular diseases. Consequently, the escalating prevalence of cardiovascular diseases is a significant driver for the growth of the cardiotonic agents market.

How Is The Cardiotonic Agents Market Examined Through Segment Analysis?

The cardiotonic agents market covered in this report is segmented –

1) By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Dosage Form: Tablet, Solution, Other Dosage Forms

4) By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C

2) By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone

3) By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine

4) By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine

5) By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol

Which Trends Are Influencing The Direction Of The Cardiotonic Agents Market?

Major companies engaged in the cardiotonic agents market are prioritizing the development of innovative solutions, such as short-term inotropic drugs, to enhance cardiac performance in patients with acute heart failure and cardiogenic shock. Short-term inotropic drugs are medications designed to temporarily improve the heart’s ability to contract, thereby elevating cardiac output. As an illustration, in June 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical enterprise, launched Dobutamine Injection, USP, presented in a 250 mg/20 mL vial. This injection is utilized for providing short-term inotropic support to adults suffering from cardiac decompensation due to reduced heart contractility, often stemming from heart disease or occurring after cardiac surgery. Its mechanism involves stimulating beta-1 receptors, which subsequently boosts heart muscle contractility and cardiac output with a rapid onset (1–2 minutes). The injection is administered intravenously and is typically given in a hospital setting under close monitoring.

Who Are The Businesses Driving Activity In The Cardiotonic Agents Market?

Major companies operating in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, Deccan Nutraceuticals Pvt. Ltd.

Access The Complete Cardiotonic Agents Market Report:

https://www.thebusinessresearchcompany.com/report/cardiotonic-agents-global-market-report

Which Region Leads The Cardiotonic Agents Market By Size?

North America was the largest region in the cardiotonic agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cardiotonic Agents Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp

Browse Through More Reports Similar to the Global Cardiotonic Agents Market 2026, By The Business Research Company

Cardiovascular Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Inotropic Agents Market Report 2026

https://www.thebusinessresearchcompany.com/report/inotropic-agents-global-market-report

Cardiovascular Monitoring And Diagnostic Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiovascular-monitoring-and-diagnostic-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795